These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20306555)

  • 21. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.
    Palella FJ; Deloria-Knoll M; Chmiel JS; Moorman AC; Wood KC; Greenberg AE; Holmberg SD;
    Ann Intern Med; 2003 Apr; 138(8):620-6. PubMed ID: 12693883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic and virological response to ART among HIV infected individuals at a tertiary hospital in Ghana.
    Obiri-Yeboah D; Pappoe F; Baidoo I; Arthur F; Hayfron-Benjamin A; Essien-Baidoo S; Kwakye-Nuako G; Ayisi Addo S
    BMC Infect Dis; 2018 May; 18(1):230. PubMed ID: 29783953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
    Keiser O; Chi BH; Gsponer T; Boulle A; Orrell C; Phiri S; Maxwell N; Maskew M; Prozesky H; Fox MP; Westfall A; Egger M;
    AIDS; 2011 Sep; 25(14):1761-9. PubMed ID: 21681057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High MIP-1β Levels in Plasma Predict Long-Term Immunological Nonresponse to Suppressive Antiretroviral Therapy in HIV Infection.
    Prebensen C; Ueland T; Michelsen AE; Lind A; Pettersen FO; Mollnes TE; Aukrust P; Dyrhol-Riise AM; Kvale D
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):395-402. PubMed ID: 26115437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increase in CD4 cell counts between 2 and 3.5 years after initiation of antiretroviral therapy and determinants of CD4 progression in India.
    Rajasekaran S; Jeyaseelan L; Raja K; Vijila S; Krithigaipriya KA; Kuralmozhi R
    J Postgrad Med; 2009; 55(4):261-6. PubMed ID: 20083872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful paediatric HIV treatment in rural primary care in Africa.
    Janssen N; Ndirangu J; Newell ML; Bland RM
    Arch Dis Child; 2010 Jun; 95(6):414-21. PubMed ID: 19880392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.
    Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D;
    AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.
    Caby F; Guihot A; Lambert-Niclot S; Guiguet M; Boutolleau D; Agher R; Valantin MA; Tubiana R; Calvez V; Marcelin AG; Carcelain G; Autran B; Costagliola D; Katlama C
    Clin Infect Dis; 2016 May; 62(10):1297-1303. PubMed ID: 26908792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.
    Boyer S; Iwuji C; Gosset A; Protopopescu C; Okesola N; Plazy M; Spire B; Orne-Gliemann J; McGrath N; Pillay D; Dabis F; Larmarange J;
    AIDS Care; 2016; 28 Suppl 3(Suppl 3):39-51. PubMed ID: 27421051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the BED capture enzyme immunoassay for HIV incidence estimation among female sex workers in Kaiyuan City, China, 2006-2007.
    Xu J; Wang H; Jiang Y; Ding G; Jia M; Wang G; Chu J; Smith K; Sharp GB; Chen RY; Jin X; Dong R; Han X; Shang H; Wang N
    Int J Infect Dis; 2010 Jul; 14(7):e608-12. PubMed ID: 20102792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis.
    Gezie LD
    BMC Res Notes; 2016 Jul; 9():377. PubMed ID: 27475982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
    Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
    J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cascade of HIV care and population viral suppression in a high-burden region of Kenya.
    Maman D; Zeh C; Mukui I; Kirubi B; Masson S; Opolo V; Szumilin E; Riche B; Etard JF
    AIDS; 2015 Jul; 29(12):1557-65. PubMed ID: 26244395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
    Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
    AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.